A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)

BACKGROUND: Metformin may have anticancer effects that are independent of its hypoglycemic effects. Retrospective studies have shown that metformin use is associated with decreased incidence of prostate cancer and prostate cancer-specific mortality. Preclinical studies suggesting additive anticancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilusic, Marijo, Toney, Nicole J., Donahue, Renee N., Wroblewski, Susan, Zibelman, Matthew, Ghatalia, Pooja, Ross, Eric A., Karzai, Fatima, Madan, Ravi A., Dahut, William L., Gulley, James L., Schlom, Jeffrey, Plimack, Elizabeth R., Geynisman, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309187/
https://www.ncbi.nlm.nih.gov/pubmed/35079115
http://dx.doi.org/10.1038/s41391-022-00492-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309187/
https://www.ncbi.nlm.nih.gov/pubmed/35079115
http://dx.doi.org/10.1038/s41391-022-00492-y

Ejemplares similares